Navigation Links
TorreyPines Therapeutics Enters into Agreement to Reduce Royalty Rates and Delay Clinical Milestone Payments Due to Eli Lilly for NGX426 and Tezampanel
Date:11/25/2008

ive disorders. The company is currently developing three product candidates: two ionotropic glutamate receptor antagonists and one muscarinic receptor agonist. Further information is available at www.torreypinestherapeutics.com.

This press release contains forward-looking statements or predictions. Such statements are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPines' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. In particular there is no guarantee that tezampanel or NGX426 will reach additional clinical milestones, complete clinical testing, or ever be commercialized, that this amendment will build stockholder value or that this amendment will enhance the commercial value of tezampanel and NGX426. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31, 2007 and TorreyPines other SEC reports. The forward-looking statements are based on current information that is likely to change and speak only as of the date hereof.

    Company contact:                             Investor contact:
    Paul Schneider                               Rhonda Chiger
    TorreyPines Therapeutics, Inc.               Rx Communications Group
    858-623-5665 X125                            (917) 322-2569
    pschneider@torreypinestherapeutics.com       rchiger@rxir.com

'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
2. TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
3. TorreyPines Therapeutics Sells Alzheimers Disease Genetics Program to Eisai
4. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
5. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
6. TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds
7. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
8. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
9. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
10. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
11. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... , May 26, 2015 ... announced the addition of Jain PharmaBiotech,s new ... and Companies" to their offering. ... molecular diagnostics technologies that will play an ... health, pharmaceutical industry, forensics and biological warfare ...
(Date:5/27/2015)... Brain Canada and the Ontario Brain Institute ... and multi-provincial research teams across Canada to address unmet ... initiative. To this amount, $1.5M is added from the ... announcement was made today at the annual meeting of ... Inez Jabalpurwala, President and CEO of Brain Canada ...
(Date:5/27/2015)... , May 27, 2015  CytomX, a biotechnology ... cancer, today announced the appointments of Bob ... Cynthia Ladd as senior vice president and ... chief financial officer of Onyx Pharmaceuticals, an Amgen ... consultant and legal counsel to several leading biotech ...
(Date:5/27/2015)... YORK , May 27, 2015  US-Australian drug discovery ... ), announced today that it will present at the Brain ... York on May 29, 2015. The venue is ... Manhattan . The Brain Tumor ... companies, the pharmaceutical industry and the investment community to promote ...
Breaking Biology Technology:Global Molecular Diagnostics Market 2015-2024 - Analysis of Key Technologies, Markets and Companies 2Global Molecular Diagnostics Market 2015-2024 - Analysis of Key Technologies, Markets and Companies 3Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 2Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 3Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 4Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 5Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 6Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 7Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 8Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 9Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences 10CytomX Expands Executive Leadership Team 2CytomX Expands Executive Leadership Team 3Novogen to Present at Brain Tumor Biotech Summit 2015 2Novogen to Present at Brain Tumor Biotech Summit 2015 3Novogen to Present at Brain Tumor Biotech Summit 2015 4Novogen to Present at Brain Tumor Biotech Summit 2015 5
... and CEO -, DALLAS, Dec. 26 Access ... Chairman Jeffrey B.,Davis has been appointed to the additional ... and CEO of the Company for health reasons. Mr.,Seiler ... "I believe that Access has an exciting future with ...
... N.J., Dec. 24 Genta,Incorporated (Nasdaq: GNTA ) ... Listing Qualifications Staff of The NASDAQ Stock Market,that it ... a minimum closing bid price of $1.00 per share. ... June 16, 2008 to regain,compliance, which requires a closing ...
... 24 Wyeth,Pharmaceuticals, a division of Wyeth (NYSE: ... patent infringement claim for lost profits and other ... launch of a,pantoprazole tablet -- a generic version ... that its product infringes the United States,PROTONIX compound ...
Cached Biology Technology:Access Pharmaceuticals Appoints Jeffrey B. Davis as CEO 2Access Pharmaceuticals Appoints Jeffrey B. Davis as CEO 3Genta Receives NASDAQ Non-Compliance Notice 2Genta Receives NASDAQ Non-Compliance Notice 3Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals' Launch of Generic Pantoprazole in Violation of PROTONIX Patent 2Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals' Launch of Generic Pantoprazole in Violation of PROTONIX Patent 3Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals' Launch of Generic Pantoprazole in Violation of PROTONIX Patent 4
(Date:5/20/2015)... May 20, 2015 ... has announced the addition of the  ... Iris Recognition Market"  report to their ... research service analyses trends in the ... and commercial sectors, globally. Despite hardware ...
(Date:5/19/2015)... 18, 2015 Fingerprint Cards (FPC) has ... FPC1145, FPC1155 and FPC1035 from one if its module partners. ... including Q3 2015 and the sensors will be used by ... values for 2015 hereby amount to 740 MSEK to date. ... 140 MSEK and a number of smaller orders not separately ...
(Date:5/19/2015)... Research and Markets ( ... the  "Genetic Testing Market Outlook 2018"  report ... ,A recent report, Genetic Testing Market Outlook ... current and future genetic testing market. A ... principles and types are covered in this ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Global Genetic Testing Market Outlook 2018 2
... It makes me sad when an article that should have ... of the student's group in the iGEM competition , check ... their bacterial 'camera'. , Using Petri dishes full of ... The University of Texas at Austin and UCSF successfully created ...
... at the Albert Einstein College of Medicine and the ... is targeted to certain regions of a cell--a process ... wound healing and cancer metastasis. Their study appears in ... Led by Drs. Robert Singer and Dr Stefan Huettelmaier, ...
... researchers has discovered that human embryonic stem cell lines accumulate ... findings do not limit the utility of the cells for ... the researchers say, but draw attention to the need to ... study how these alterations affect the cells' behavior. The researchers' ...
Cached Biology News:Student scientists create living bacterial photographs 2Student scientists create living bacterial photographs 3Einstein scientists discover how protein crucial for motion is synthesised at the right place in the cell 2Embryonic stem cells accrue genetic changes 2Embryonic stem cells accrue genetic changes 3Embryonic stem cells accrue genetic changes 4
Mouse monoclonal [0.N.509] to PCTAIRE2 ( Abpromise for all tested applications). entrezGeneID: 5128 SwissProtID: Q00537...
MMP-2 / MMP-9 Inhibitor IV is a potent, selective, slow binding and mechanism based inhibitor of human gelatinases. • Molecular weight: 306.4 • Molecular Formula: C(15)H(14)O(3)S(2). &bul...
... Spin Columns contain a proprietary high-performance desalting ... desalting and protein-recovery characteristics compared to other ... as 25 g/ml of protein can be ... 95% retention of salts and other small ...
Rabbit polyclonal to GABA A Receptor gamma 2 ( Abpromise for all tested applications). entrezGeneID: 2566 SwissProtID: P18507...
Biology Products: